Should we use the oral selective IP receptor agonist selexipag off-label in children with pulmonary arterial hypertension?

We discuss the currently available data on the use of the prostacyclin mimetic selexipag in children and adolescents with pulmonary arterial hypertension (PAH). Future indications may include transitioning from intravenous prostacyclin/prostacyclin analog to oral selexipag, and vice versa, or adding...

Descripción completa

Detalles Bibliográficos
Autores principales: Koestenberger, Martin, Hansmann, Georg
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2018
Materias:
Research Letter
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6161208/
https://www.ncbi.nlm.nih.gov/pubmed/30260767
http://dx.doi.org/10.1177/2045894018793580

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6161208/
https://www.ncbi.nlm.nih.gov/pubmed/30260767
http://dx.doi.org/10.1177/2045894018793580

Ejemplares similares